Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH
详细信息 查看全文
- 作者：William J. Valentine (1)
Andrew J. Palmer (1)
Katrina M. Erny-Albrecht (1)
Joshua A. Ray (1)
David Cobden (2)
Volker Foos (1)
Francisco M. Lurati (1)
Stéphane Roze (1) - 关键词：type 1 diabetes ; NPH ; detemir ; insulin glargine ; modeling ; costs ; life expectancy ; quality ; adjusted life expectancy ; cost ; effectiveness
- 刊名：Advances in Therapy
- 出版年：2006
- 出版时间：March 2006
- 年：2006
- 卷：23
- 期：2
- 页码：191-207
- 全文大小：215KB
- 参考文献：1. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med. 1993; 329: 977-86. CrossRef
2. American Association of Clinical Endocrinologists.Medical Guidelines for the Management of Diabetes Mellitus. Jacksonville, Fla: AACE; 2002.
3. The DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial.Am J Med. 1991; 90: 450-59.
4. The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial.Diabetes Care. 1988; 11: 567-73. CrossRef
5. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics.Diabetes Care. 1984; 7: 188-99. CrossRef
6. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.Diabetes Care. 2005; 28: 1107-112. CrossRef
7. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.Diabetologia. 2004; 47: 622-29. CrossRef
8. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin.Diabet Med. 2005; 22: 850-57. CrossRef
9. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.Diabetes Care. 2004; 27: 1081-087. CrossRef
10. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen.Clin Ther. 2004; 26: 724-36. CrossRef
11. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.Intern Med J. 2005; 35: 536-42. CrossRef
12. Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.Curr Med Res Opin. 2004; 20: 1703-710. CrossRef
13. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.Diabetes Metab Res Rev. 2005; 21: 545-53. CrossRef
14. Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy: an observational study of 100 consecutive patients followed for a mean of 2 years.Diabet Med. 2002; 19: 746-51. CrossRef
15. Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.Curr Med Res Opin. 2004; 20: 1729-746. CrossRef
16. Pieber TR, Treichel H-C, Robertson LI, Mordhorst L, Gall M-A. Insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes [abstract].Diabetologia. 2005; 48(suppl 1): A92.
17. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.Diabetes. 2004; 53: 1614-620. CrossRef
18. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.Curr Med Res Opin. 2004; 20(8 suppl): 5-6. CrossRef
19. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies.Curr Med Res Opin. 2004; 20(suppl 1): S27-S40. CrossRef
20. Ray J, Valentine WJ, Roze S, et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasis insulin aspart 70/30 versus insulin glargine in the US.Diabetes Obes Metab. In press.
21. Tarn T, Smith M. Pharmacoeconomic guidelines around the world.ISPOR Connections. 2004: 15-8.
22. Davies R, Wittrup-Jensen KU, Peters JR, Morrissey M, Currie CJ.The Impact on Health-Related Quality of Life (EQ-5D Index) in People With Type 1 Diabetes Who Experience Severe Hypoglycaemia. Dusseldorf, Germany: European Association for the Study of Diabetes; 2005.
23. National Institute for Clinical Excellence.Technology Appraisal Guidance. No. 53. Guidance on the Use of Long-Acting Insulin Analogues for the Treatment of Diabetes—Insulin Glargine. London, UK: NICE; 2002.
24. Bullano MF, Al Zakwani IS, Fisher MD, Menditto L, Willey VJ. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.Curr Med Res Opin. 2005; 21: 291-98. CrossRef
25. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.Health Econ. 1997; 6: 327-40. CrossRef
26. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes.Diabetes Care. 2000; 23: 390-04. CrossRef
27. Nordfeldt S, Ludvigsson J. Fear and other disturbances of severe hypoglycaemia in children and adolescents with type 1 diabetes mellitus.J Pediatr Endocrinol Metab. 2005; 18: 83-1.
28. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.JAMA. 1998; 280: 140-46. CrossRef
29. De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic microvascular complications in type 1 diabetic patients.Diabetes Care. 2005; 28: 1649-655. CrossRef
30. Lee AJ, Morgan CL, Morrissey M, Wittrup-Jensen KU, Kennedy-Martin T, Currie CJ. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with type 1 diabetes, type 2 diabetes and with no diagnosed diabetes.Diabet Med. 2005; 22: 1482-486. CrossRef
31. Zhang Q, Menditto L. Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample.Am J Ther. 2005; 12: 337-43. CrossRef - 作者单位：William J. Valentine (1)
Andrew J. Palmer (1)
Katrina M. Erny-Albrecht (1)
Joshua A. Ray (1)
David Cobden (2)
Volker Foos (1)
Francisco M. Lurati (1)
Stéphane Roze (1)
1. CORE-Center for Outcomes Research, Bündtenmattstrasse 40, 4102, Binningen, Switzerland
2. Novo Nordisk Inc., Princeton, NJ, USA
文摘
The purpose of this study was to compare in clinical and economic terms the long-acting insulin analogue detemir with intermediate-acting Neutral Protamine Hagedorn (NPH) insulin and with long-acting insulin glargine. Investigators used the validated Center for Outcomes Research (CORE) Diabetes Model to project clinical and cost outcomes over a 35-year base case time horizon; outcome data were extracted directly from randomized, controlled trials designed to compare detemir with NPH and with insulin glargine. Modeled patient characteristics were derived from corresponding trials, and simulations incorporated published quality-of-life utilities with cost data obtained from a Medicare perspective. Detemir, when compared with NPH, increased quality-adjusted life expectancy by 0.698 quality-adjusted life-years (QALYs). Lifetime direct medical costs were increased by $10,451 per patient, although indirect costs were reduced by $4688. On the basis of direct costs, the cost per QALY gained with detemir was $14,974. In comparison with glargine, detemir increased quality-adjusted life expectancy by 0.063 QALYs, reduced direct medical costs by $2072 per patient, and decreased indirect costs by $3103 (dominant). Reductions in diabetes-related comorbidities were also associated with detemir in both instances, most notably in the complications of retinopathy and nephropathy. Relative reductions in rates of complications were greatest in the comparison of detemir with NPH. Results were most sensitive to variation in hemoglobin A1c (HbA1c) levels. However, variation among any of the key assumptions, including HbA1c, did not alter the relative results. Detemir represents an attractive clinical and economic intervention in the US health care setting compared with both NPH insulin and insulin glargine.